These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8277209)

  • 41. Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities?
    Valdés Olmos RA; Hoefnagel CA
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):929-31. PubMed ID: 15042326
    [No Abstract]   [Full Text] [Related]  

  • 42. Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy.
    Pareri AU; Koijam AS; Kumar C
    Anticancer Agents Med Chem; 2022; 22(10):1845-1858. PubMed ID: 34477531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radionuclides in oncology clinical practice - review of the literature.
    Luna Pais H; Alho I; Vendrell I; Mansinho A; Costa L
    Dalton Trans; 2017 Oct; 46(42):14475-14487. PubMed ID: 28975182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic radionuclides in nuclear medicine: current and future prospects.
    Yeong CH; Cheng MH; Ng KH
    J Zhejiang Univ Sci B; 2014 Oct; 15(10):845-63. PubMed ID: 25294374
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).
    Denardo GL; Macey DJ
    Cancer Biother Radiopharm; 2010 Oct; 25(5):507-9. PubMed ID: 20849311
    [No Abstract]   [Full Text] [Related]  

  • 46. Dosimetry in Peptide radionuclide receptor therapy: a review.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical assessment of radiation doses using labelled antibodies for therapy.
    Myers MJ; Epenetos AA; Hooker G
    Int J Rad Appl Instrum B; 1986; 13(4):437-46. PubMed ID: 3793499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential and pitfalls of therapy with alpha-particles.
    Welch MJ
    J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
    [No Abstract]   [Full Text] [Related]  

  • 49. Advances in cancer therapy with radiolabeled monoclonal antibodies.
    Goldenberg DM; Sharkey RM
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):248-64. PubMed ID: 17043623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances in radionuclide therapy.
    Srivastava S; Dadachova E
    Semin Nucl Med; 2001 Oct; 31(4):330-41. PubMed ID: 11710775
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide receptor radionuclide therapy: an overview.
    Dash A; Chakraborty S; Pillai MR; Knapp FF
    Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risks to normal tissues from radionuclide therapy.
    Meredith R; Wessels B; Knox S
    Semin Nucl Med; 2008 Sep; 38(5):347-57. PubMed ID: 18662556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Measurement of dose in radionuclide therapy by using Cerenkov radiation.
    Ai Y; Tang X; Shu D; Shao W; Gong C; Geng C; Zhang X; Yu H
    Australas Phys Eng Sci Med; 2017 Sep; 40(3):695-705. PubMed ID: 28808904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal Function Assessment During Peptide Receptor Radionuclide Therapy.
    Erbas B; Tuncel M
    Semin Nucl Med; 2016 Sep; 46(5):462-78. PubMed ID: 27553471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel prodrugs for targeting diagnostic and therapeutic radionuclides to solid tumors.
    Kassis AI; Korideck H; Wang K; Pospisil P; Adelstein SJ
    Molecules; 2008 Feb; 13(2):391-404. PubMed ID: 18305426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Therapeutic advances of nuclear medicine in oncology].
    Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
    Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of lipid-soluble complexes in targeted tumor therapy.
    Thakur ML; Coss R; Howell R; Vassileva-Belnikolovska D; Liu J; Rao SP; Spana G; Wachsberger P; Leeper DL
    J Nucl Med; 2003 Aug; 44(8):1293-300. PubMed ID: 12902421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The promise of immuno-PET in radioimmunotherapy.
    Verel I; Visser GW; van Dongen GA
    J Nucl Med; 2005 Jan; 46 Suppl 1():164S-71S. PubMed ID: 15653665
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiation Safety and Accidental Radiation Exposures in Nuclear Medicine.
    Marengo M; Martin CJ; Rubow S; Sera T; Amador Z; Torres L
    Semin Nucl Med; 2022 Mar; 52(2):94-113. PubMed ID: 34916044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.